Eli Lilly Sues Teva for Patent Infringement and seek Declaratory Judgement

Eli Lilly & Co. have sued Teva Pharmaceutical Industries Ltd., alleging infringement of two U.S. patents that are used in Gemzar, a cancer drug .

According to the complaint filed Sept. 26 in federal court in Indianapolis, Teva asked the FDA for permission to market a copy of Gemzar, and Lilly alleges that this would be a violation of their patents.

Lilly is seeking a declatory judgment that its patents are valid and that Teva would infringe the patents by manufacturing a generic version of the drug. Lilly is also seeking to prohibit Teva’s U.S. Division from using the patented technology.



Categories: Intellectual Property, Israel Related, News, Opinion, Patents, pharmaceuticals, pharmaceuticals and Biotechnology, Teva

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: